These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36498918)

  • 1. [
    Kanellopoulos P; Nock BA; Greifenstein L; Baum RP; Roesch F; Maina T
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [
    Nock BA; Kanellopoulos P; Moon ES; Rouchota M; Loudos G; Ballal S; Yadav MP; Bal C; Mishra P; Sheokand P; Roesch F; Maina T
    Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Head-to-Head Comparison of SSTR Antagonist [
    Viswanathan R; Ballal S; Yadav MP; Roesch F; Sheokand P; Satapathy S; Tripathi M; Agarwal S; Moon ES; Bal C
    Pharmaceuticals (Basel); 2024 Feb; 17(3):. PubMed ID: 38543061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
    Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
    J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of
    Zhu W; Cheng Y; Jia R; Zhao H; Bai C; Xu J; Yao S; Huo L
    J Nucl Med; 2021 Oct; 62(10):1398-1405. PubMed ID: 33579804
    [No Abstract]   [Full Text] [Related]  

  • 6. Novel bifunctional DATA chelator for quick access to site-directed PET
    Nock BA; Kaloudi A; Nagel J; Sinnes JP; Roesch F; Maina T
    Dalton Trans; 2017 Oct; 46(42):14584-14590. PubMed ID: 28675208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Neuropeptide Y1 Receptor for Cancer Imaging by Positron Emission Tomography Using Novel Truncated Peptides.
    Zhang C; Pan J; Lin KS; Dude I; Lau J; Zeisler J; Merkens H; Jenni S; Guérin B; Bénard F
    Mol Pharm; 2016 Nov; 13(11):3657-3664. PubMed ID: 27669056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity Comparison of
    Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Biodistribution, and Radiation Dosimetry of
    Nicolas GP; Beykan S; Bouterfa H; Kaufmann J; Bauman A; Lassmann M; Reubi JC; Rivier JEF; Maecke HR; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):909-914. PubMed ID: 29025985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of
    Zhu W; Jia R; Yang Q; Cheng Y; Zhao H; Bai C; Xu J; Yao S; Huo L
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1613-1622. PubMed ID: 34874478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
    Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [
    Xie Q; Liu T; Ding J; Zhou N; Meng X; Zhu H; Li N; Yu J; Yang Z
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3129-3140. PubMed ID: 33630145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
    J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-Head Comparison of
    Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
    J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
    [No Abstract]   [Full Text] [Related]  

  • 16. Design, Synthesis, and Biological Evaluation of
    Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
    Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Instant kit preparation of
    Sinnes JP; Nagel J; Waldron BP; Maina T; Nock BA; Bergmann RK; Ullrich M; Pietzsch J; Bachmann M; Baum RP; Rösch F
    EJNMMI Res; 2019 May; 9(1):48. PubMed ID: 31123943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
    Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR
    J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.
    Ishizaki A; Mishiro K; Shiba K; Hanaoka H; Kinuya S; Odani A; Ogawa K
    Ann Nucl Med; 2019 Apr; 33(4):244-251. PubMed ID: 30604401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.